ICPT * Stock Overview Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Intercept Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Intercept Pharmaceuticals Historical stock prices Current Share Price US$329.00 52 Week High US$0 52 Week Low US$0 Beta 1.27 1 Month Change 0% 3 Month Change 0% 1 Year Change 0% 3 Year Change -83.98% 5 Year Change n/a Change since IPO -78.86%
Recent News & Updates
Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA) Nov 13
Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA Oct 17
Intercept Announces Statement on FDA Advisory Committee Meeting Sep 16
Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024 Jun 06
Intercept Pharmaceuticals, Inc. Files Form 15 Nov 21
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023 Nov 15 See more updates
Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA) Nov 13
Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA Oct 17
Intercept Announces Statement on FDA Advisory Committee Meeting Sep 16
Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024 Jun 06
Intercept Pharmaceuticals, Inc. Files Form 15 Nov 21
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023 Nov 15
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023 Nov 14
Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023 Nov 11 Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors Oct 24
Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million. Sep 27
Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023 Aug 03
Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage Jun 23
Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023 Jun 08
Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021) Mar 03
U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash Jan 20
Forecast breakeven date pushed back to 2025 Dec 31
Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH Dec 24 Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 Nov 07
Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021) Nov 03
Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 26
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint Oct 01
Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology Sep 21
Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021) Aug 04
Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 28
Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022 Jul 27
Forecast breakeven date moved forward to 2022 Jul 18
Forecast breakeven date moved forward to 2022 Jul 08
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) Jul 08
Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline Jun 07 Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance
Forecast breakeven date moved forward to 2022 May 31 Shareholder Returns ICPT * MX Biotechs MX Market 7D 0% 0% 0% 1Y 0% 0% 0%
See full shareholder returns
Return vs Market: ICPT * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility Is ICPT *'s price volatile compared to industry and market? ICPT * volatility ICPT * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: ICPT * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ICPT *'s volatility change over the past year.
About the Company Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development.
Show more Intercept Pharmaceuticals, Inc. Fundamentals Summary How do Intercept Pharmaceuticals's earnings and revenue compare to its market cap? ICPT * fundamental statistics Market cap Mex$8.54b Earnings (TTM ) -Mex$3.00b Revenue (TTM ) Mex$5.09b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ICPT * income statement (TTM ) Revenue US$294.52m Cost of Revenue US$983.00k Gross Profit US$293.54m Other Expenses US$466.84m Earnings -US$173.30m
Last Reported Earnings
Mar 31, 2023
Earnings per share (EPS) -4.16 Gross Margin 99.67% Net Profit Margin -58.84% Debt/Equity Ratio 495.7%
How did ICPT * perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/06/12 04:33 End of Day Share Price 2023/03/15 00:00 Earnings 2023/03/31 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Intercept Pharmaceuticals, Inc. is covered by 28 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Birchenough BMO Capital Markets Equity Research Geoffrey Meacham BofA Global Research Mayank Mamtani B. Riley Securities, Inc.
Show 25 more analysts 